TABLE 2.
Baseline Recipient Immunologic Risk and Immunosuppression Stratified and Compared by Induction Therapy
| Characteristic | IL-2RA Induction (n = 8157) | Cytolytic Induction (n = 16,927) | P Value |
|---|---|---|---|
| Median HLA mismatches (IQR) | 4 (3, 5) | 4 (3, 5) | |
| 0 Mismatches | 5.2% | 4.0% | |
| 1 Mismatch | 2.8% | 2.0% | |
| 2 Mismatches | 8.0% | 5.9% | <0.001 |
| 3 Mismatches | 18.3% | 15.0% | |
| 4 Mismatches | 21.2% | 23.9% | |
| 5 Mismatches | 28.1% | 31.9% | |
| 6 Mismatches | 16.4% | 17.2% | |
| Median type A mismatches (IQR) | 1 (1, 2) | 1 (1, 2) | <0.001 |
| Median type B mismatches (IQR) | 2 (1, 2) | 2 (1, 2) | <0.001 |
| Median type DR mismatches (IQR) | 1 (1, 2) | 1 (1, 2) | <0.001 |
| Median current PRA (%, IQR) | 0 (0, 3) | 0 (0, 15) | <0.001 |
| Current PRA >20% | 11.4% | 22.6% | <0.001 |
| Median peak PRA (%, IQR) | 0 (0, 13) | 3 (0, 35) | <0.001 |
| Peak PRA >20% | 19.5% | 30.7% | <0.001 |
| Mean cold ischemic time (h ± SD) | 14.6 ± 10.2 | 16.4 ± 11.3 | <0.001 |
| Previous transplant | 6.0% | 11.6% | <0.001 |
| Delayed graft function | 20.6% | 26.7% | <0.001 |
| Baseline immunosuppression | |||
| Tacrolimus | 65.9% | 83.9% | <0.001 |
| Cyclosporine | 28.5% | 10.7% | <0.001 |
| Mycophenolate | 87.8% | 88.0% | 0.601 |
| Azathioprine | 1.8% | 1.1% | <0.001 |
| mTOR inhibitor | 10.9% | 9.0% | <0.001 |
| Steroid withdrawal | 8.0% | 29.2% | <0.001 |
IL-2RA indicates IL-2 receptor antibody; IQR, interquartile ranges; PRA, panel reactive antibody; SD, standard deviation.